Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer ...
Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a marker of kidney damage,2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose ...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,...
Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to […]
Boehringer Ingelheim today announced promising 14week Phase II data for BI 690517 a novel selective aldosterone synthase inhibitor ASi.